Every Form 4 that Guardant Health, Inc. (GH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GH filings page.
Guardant Health, Inc. (GH) director Roberto Mignone reported the conversion of 264 restricted stock units into 264 common shares on October 21, 2026. After the transaction, he directly held 10,538 common shares and 6,336 restricted stock units. The award, granted November 8, 2024, vests over four years: 25% vested October 21, 2025, and the remaining 75% vests monthly over the three-year period thereafter.
Guardant Health, Inc. director Medina Manuel Hidalgo reported converting 232 restricted stock units into 232 common shares on October 17, 2026. The reported post-transaction positions were 4,873 restricted stock units and 5,252 common shares, both held directly. The award, granted July 17, 2024, vests over four years: 25% vested on July 17, 2025, and the remaining 75% vests monthly for the three-year period thereafter.
Guardant Health director Tariq Musa sold 116 shares of common stock on October 16, 2026, at $165.88 per share under a Rule 10b5-1 trading plan. On October 15, he acquired 250 common shares through conversion of 250 restricted stock units; 1,250 restricted stock units were reported following that transaction.
Guardant Health, Inc. (GH) director Alex M. Azar II sold 69 shares of common stock on October 14, 2026, at $159.89 per share. The transaction was identified as a sale in the open market or a private transaction and was made under a Rule 10b5-1 trading plan. Afterward, Azar reported directly holding 893 shares.
Guardant Health, Inc. director Alex M. Azar II reported converting 137 restricted stock units into 137 shares of common stock on October 12, 2026. After the transaction, he directly held 4,816 restricted stock units and 962 shares of common stock.
The award was granted September 12, 2025 and vests over four years: 25% vested September 12, 2026, and the remaining 75% vests monthly for the three-year period thereafter.
On October 1, 2026, Guardant Health, Inc. Chief Legal Officer John G. Saia converted four restricted stock unit awards into 7,063 shares of common stock. The company retained 3,706 shares to meet tax withholding obligations tied to the awards; the amount retained was not in excess of the tax liability. The reported price for the retained shares was $174.75 per share.
Guardant Health, Inc. (GH) Chief People Officer Terilyn J. Monroe reported conversion of 2,659 and 1,360 restricted stock units into the same respective numbers of common shares on October 1, 2026. On that date, 2,098 shares were retained by the company to meet tax withholding obligations tied to vesting, at $174.75 per share. The footnote states the amount retained was not in excess of the tax liability.
Guardant Health, Inc. Chief Information Officer Kumud Kalia exercised restricted stock units that converted into 6,046 shares of common stock on October 1, 2026. The company retained 3,067 shares for tax withholding, reported at $174.75 per share; the retained amount did not exceed the tax liability. No Rule 10b5-1 plan is reported.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported conversion of 7,416 restricted stock units into common stock on October 1, 2026, and 3,143 common shares retained by the Company for tax withholding. The retained shares met tax obligations associated with vesting an installment of restricted stock units.
Guardant Health, Inc. Chief Technology Officer Darya Chudova reported conversion of 8,033 restricted stock units into common stock on October 1, 2026. On the same date, the company retained 4,320 shares to meet the award-holder’s tax withholding obligations, at a reported price of $174.75 per share. The filing states the amount retained did not exceed the tax liability.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell reported conversion of three restricted stock unit awards into 2,085, 3,324 and 1,871 shares of common stock on October 1, 2026. Guardant Health retained 3,914 common shares to meet the award-holder’s tax-withholding obligation, at a reported $174.75 per share; the related footnote says the amount retained did not exceed the tax liability.
Guardant Health, Inc. co-CEO AmirAli Talasaz reported restricted stock unit conversions and common-share acquisitions by the Talasaz and Eskandari 2017 Family Trust. On September 30, 2026, 2,817 RSUs converted into 2,817 common shares held by the trust, and 1,428 shares were withheld for tax liability. On October 1, 2026, 23,997 and 9,716 RSUs converted into corresponding common shares held by the trust; 17,087 shares were withheld for tax liability.
Guardant Health, Inc. Co-Chief Executive Officer and director Helmy Eltoukhy reported restricted stock unit conversions resulting in 36,530 common shares held indirectly through the Helmy A. Eltoukhy Revocable Trust. The company retained 18,515 shares to meet tax-withholding obligations: 1,428 shares at $178.36 per share on September 30, 2026, and 17,087 shares at $174.75 per share on October 1, 2026. No Rule 10b5-1 plan is reported.
Guardant Health, Inc. (GH) director Roberto Mignone reported the vesting and conversion of 264 Restricted Stock Units into 264 shares of Common Stock on September 21, 2026, at a stated price of $0.00 per share. After these events, he holds 10,274 shares of Common Stock and 6,600 Restricted Stock Units, all held directly. The Restricted Stock Units were granted on November 8, 2024 and vest over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the following three years.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported the vesting and conversion of 232 Restricted Stock Units232 shares of Common Stock5,020 shares of Common Stock
The RSUs relate to an award granted on July 17, 2024 that vests over four years, with 25% vesting on July 17, 2025 and the remaining 75% vesting monthly over the following three years. No Rule 10b5-1 trading plan is reported for these transactions.
Guardant Health, Inc. (GH) reported that Chief Technology Officer Darya Chudova sold 7,738 shares of common stock on September 15, 2026 in a sale characterized as an open market or private transaction at $178.00 per share. After this transaction, she directly holds 70,635 shares of Guardant Health common stock. No Rule 10b5-1 trading plan is reported for this sale.
Guardant Health, Inc. (GH) director Steve E. Krognes reported selling a total of 6,674 shares of common stock on September 16, 2026 in four open-market or private transactions. Each sale was reported at a weighted average price with price ranges from $173.98 to $177.945 per share, and no Rule 10b5-1 trading plan is indicated.
Guardant Health, Inc. (GH) director Alex M. Azar II reported selling 826 shares of common stock on September 16, 2026 in a sale described as occurring in the open market or a private transaction at a reported price of $175.00 per share. The transaction was reported as made under a Rule 10b5-1 trading plan, and following the sale he held 825 shares of Guardant Health common stock directly.
Guardant Health, Inc. (GH) director Tariq Musa reported a small set of equity transactions involving company stock. On September 15, 2026, 249 Restricted Stock Units vested and were converted into 249 shares of common stock, increasing his directly held common shares. The same RSU award, granted on March 6, 2023, vests over four years, with 25% having vested on March 15, 2024 and the remaining 75% vesting monthly over the following three years, leaving 1,500 RSUs reported as outstanding after this vesting event. On September 16, 2026, he sold 116 shares of common stock at a reported price of $175.00 per share in a transaction affirmed as made under a Rule 10b5-1 trading plan.
Guardant Health, Inc. (GH) reported that director Alex M. Azar II had 1,651 Restricted Stock Units convert into 1,651 shares of Common Stock on September 12, 2026, at a stated price of $0.00 per share, reflecting a vesting event rather than a market sale.
The Restricted Stock Unit award was granted on September 12, 2025 and vests over four years, with 25% of the shares vesting on September 12, 2026 and the remaining 75% vesting monthly over the following three years. After this vesting, 4,953 Restricted Stock Units and 1,651 Common Stock shares are held directly, and no Rule 10b5-1 trading plan is reported.
Guardant Health, Inc. (GH) reported that Chief Information Officer Kumud Kalia sold 4,000 shares of common stock on September 11, 2026 in an open‑market or private transaction at a weighted average price of $158.0483 per share. After this sale, the officer directly held 39,794 shares of Guardant Health common stock. The sale price reflects multiple individual trades executed between $157.99 and $158.215 per share. No Rule 10b5-1 trading plan is reported for this transaction.
Guardant Health, Inc. (GH) reported insider transactions by Co-Chief Executive Officer and director Helmy Eltoukhy involving only indirect holdings. On August 26, 2026, entities associated with him restructured 50,000 shares of common stock, moving 25,000 shares from the Helmy A. Eltoukhy Revocable Trust to The Eltoukhy Foundation, leaving the foundation holding 60,000 shares. The same trust also made a bona fide gift of 30,000 shares to a Donor Advisory Fund at Vanguard. All transactions were reported at a price of $0.00 per share and reflect ownership changes and charitable giving rather than market purchases or sales.
Guardant Health, Inc. (GH) reported that Co-Chief Executive Officer and director AmirAli Talasaz, through indirect ownership by the Talasaz Family Foundation, sold a total of 37,500 shares of common stock on August 21, 2026 in open-market or private transactions. The sales occurred in three weighted-average price tranches between $167.81 and $170.50 per share. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Guardant Health, Inc. (GH) director Roberto Mignone reported the vesting and settlement of equity awards. On August 21, 2026, 264 Restricted Stock Units were converted into 264 shares of Common Stock at $0.00 per share. Following these transactions, he holds 10,010 Common shares and 6,864 RSUs, all as direct ownership. The RSUs were from a November 8, 2024 grant that vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the next three years.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported the vesting and conversion of restricted stock units into common stock. On August 17, 2026, 232 restricted stock units were converted into 232 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he held 4,788 shares of common stock directly and 5,337 restricted stock units, which continue to vest under an award granted on July 17, 2024.
Guardant Health, Inc. (GH) director Tariq Musa reported a combination of RSU vesting and share sales. On August 15, 2026, 250 Restricted Stock Units were converted into 250 shares of common stock, increasing direct holdings to 1,749 shares. On August 17, 2026, he sold 116 common shares at $156.45 per share in an open-market or private transaction. The RSU award was granted on March 6, 2023 and vests over four years, with 25% vested March 15, 2024 and the remaining 75% vesting monthly over the following three years. The filing indicates these transactions were effected under a Rule 10b5-1 trading plan.
Guardant Health, Inc. executive Terilyn J. Monroe, Chief People Officer, exercised stock options covering 46,300 shares of common stock on 2026-08-12 (32,288 shares at an exercise price of $20.14 and 14,012 shares at $28.61). She then sold 46,300 common shares in multiple open-market or private transactions at weighted average prices ranging from $162.80 to $168.02. The exercised options were from awards granted on February 26, 2024 and November 8, 2024, each vesting over three years with 33% vesting after roughly one year and the remaining 67% in equal monthly installments over the next two years. The filing does not affirm trading under a Rule 10b5-1 plan.
Guardant Health, Inc. director and Co-Chief Executive Officer Helmy Eltoukhy reported two bona fide gift transactions involving common stock on 2026-08-11. A total of 35,000 shares of Guardant Health common stock were transferred from the Helmy A. Eltoukhy Revocable Trust, reducing that trust’s indirect holdings to 1,995,934 shares. On the same date, 35,000 shares were recorded as acquired as indirect holdings of The Eltoukhy Foundation. A footnote states that these entries reflect changes in form of ownership from the revocable trust to The Eltoukhy Foundation, indicating an internal re-titling of shares rather than an open-market purchase or sale.
Guardant Health, Inc. director and Co-Chief Executive Officer AmirAli Talasaz reported internal transfers of common stock interests involving family entities. On 2026-08-10, 75,000 shares were transferred as a bona fide gift from the Talasaz and Eskandari 2017 Family Trust, reducing that indirect holding to 1,824,351 shares, and 75,000 shares were received by The Talasaz Family Foundation, which now holds 75,000 shares. A footnote states these transactions reflect changes in form of ownership between the trust and the foundation.
Guardant Health, Inc. executive John G. Saia, Chief Legal Officer, reported a bona fide gift of 800 shares of common stock on 2026-08-10. The gift reflects a change in form of ownership due to a transfer to a donor-advised fund within the Saia Family Foundation. Following this charitable transfer, Saia directly holds 38,991 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported option exercises and share sales on August 10, 2026. He exercised stock options covering 63,605 shares of common stock, including 35,412 shares at an exercise price of $110.49 per share from an award granted August 3, 2021, which is now fully vested, and 28,193 shares at an exercise price of $28.37 per share from an award granted December 13, 2023 that continues to vest over a three-year period. Freeman then sold 63,605 shares of common stock in open-market transactions at weighted average prices per share ranging from approximately $167.12 to $170.67, with the exact breakdown of shares sold at each price available upon request as noted in the footnotes.
Guardant Health director Manuel Hidalgo Medina exercised stock options for 950 shares on August 5, 2026 at an exercise price of $32.5500 per share, receiving 950 common shares. He then sold 1,700 common shares in two trades at $163.9450 and $164.6051 per share. After the exercise, he continued to hold stock options covering 12,079 shares that were granted on July 17, 2024 and vest 25% on July 17, 2025, with the remaining 75% vesting monthly over the following three years.
Guardant Health, Inc. director Ian T. Clark exercised stock options and sold shares held through a family trust. On 2026-08-04, options for 2,255 and 6,833 shares of common stock were exercised at strike prices of $91.11 and $50.57. The Thornton-Clark Family Trust then sold a total of 14,180 common shares at weighted average prices of $158.98 and $158.80, within disclosed price ranges.
Guardant Health director Roberto Mignone exercised a restricted stock unit award on July 21, 2026, converting 264 Restricted Stock Units into 264 shares of Common Stock at $0.00 per share. Following this transaction, he directly holds 9,746 Common shares and 7,128 Restricted Stock Units. The RSU grant, awarded on November 8, 2024, vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the subsequent three years. The transaction was not marked as made under a Rule 10b5-1 trading plan, as the related checkbox was left unchecked.
Guardant Health, Inc. director Manuel Hidalgo Medina reported the vesting and settlement of 232 Restricted Stock Units into 232 shares of common stock on July 17, 2026. After these transactions he directly holds 5,306 common shares and 5,569 remaining RSUs from a four-year grant awarded July 17, 2024.
Guardant Health director Tariq Musa reported transactions in company equity. On July 15, 2026, he converted 250 Restricted Stock Units into 250 shares of common stock at no cash cost, leaving 1,999 RSUs outstanding. On July 16, he sold 116 shares of common stock in an open-market sale at $163.29 per share and held 11,182 shares afterward.
Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity tied to restricted stock units (RSUs). On 2026-07-01, several RSU awards vested and converted into a total of 7,063 shares of Guardant Health common stock at a stated price of $0.00 per share.
To cover tax obligations from this vesting, the company retained 3,707 shares at a price of $170.77 per share, according to the filing footnotes. These transactions reflect RSU vesting, derivative exercises, and tax withholding, not open-market purchases or sales.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity. On July 1, 2026, restricted stock units converted into a total of 4,020 shares of Common Stock, reflecting scheduled vesting of prior awards. The company retained 2,099 shares at $170.77 per share to cover Ms. Monroe’s tax withholding obligations, rather than through an open-market sale. Following these transactions, she continues to hold both common shares and unvested restricted stock units as part of her compensation.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported routine equity compensation activity. On 2026-07-01, several batches of restricted stock units vested and were converted into a total of 6,046 shares of common stock at a conversion price of $0.00 per share.
To cover associated tax obligations from this vesting, 3,066 shares of common stock were withheld by the company at a value of $170.77 per share, as described in the footnotes. These transactions reflect compensation-related vesting and tax withholding rather than open-market buying or selling.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported compensation-related equity activity involving restricted stock units. On July 1, 2026, RSU awards vested and were converted into a total of 7,414 shares of common stock, reflecting derivative exercises rather than open-market purchases.
To cover tax obligations arising from this vesting, 3,141 shares of common stock were retained by the company at a value of $170.77 per share, as noted in the footnotes. The transactions do not include any open-market buying or selling, and are characterized as routine equity compensation and tax withholding events.
Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity involving restricted stock units and related tax withholding. On July 1, 2026, several restricted stock unit awards converted into common stock, reflected as multiple exercise transactions.
In connection with the vesting, 4,318 shares of common stock were retained by Guardant Health at $170.77 per share to cover her tax withholding obligations, as described in the footnotes. Following these transactions, Chudova directly held 78,373 shares of Guardant Health common stock.
Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity involving restricted stock units that vested into common stock. On July 1, 2026, RSU conversions delivered 7,278 shares of common stock, while 3,914 shares were withheld at $170.77 per share to cover tax obligations, rather than sold in the open market.
Guardant Health, Inc. director and Co-Chief Executive Officer Helmy Eltoukhy, through the Helmy A. Eltoukhy Revocable Trust, reported routine equity compensation activity involving restricted stock units and related tax withholding.
On June 30 and July 1, 2026, a total of 36,529 restricted stock units were converted into an equal number of shares of common stock at a conversion price of $0.00 per share. To satisfy tax withholding obligations tied to these vestings, 18,514 shares of common stock were retained by the company at prices of $150.03 and $170.77 per share, as noted in the footnotes. These F-code dispositions reflect payment of tax liabilities rather than open-market sales.
Guardant Health, Inc. Co-Chief Executive Officer AmirAli Talasaz reported routine equity compensation activity involving restricted stock units. On June 30 and July 1, 2026, a total of 36,529 restricted stock units converted into common stock through derivative exercises, reflecting scheduled vesting.
Across the same dates, 18,514 common shares were withheld and retained by the company at prices of $150.03 and $170.77 per share to cover tax liabilities associated with these vesting events. The transactions occurred through the Talasaz and Eskandari 2017 Family Trust and do not involve any open-market purchases or sales.
Guardant Health director Steve E. Krognes reported an exercise of restricted stock units that delivered 155 shares of common stock on June 30, 2026. These RSUs were from an award granted on August 9, 2022, which vested 25% on June 30, 2023 and the remaining 75% over the following three years.
After this derivative exercise, Krognes directly holds 14,580 shares of Guardant Health common stock. This Form 4 reflects a compensation-related vesting and conversion of equity awards, with no open-market buying or selling reported in this filing.
Guardant Health Chief Information Officer Kumud Kalia reported small, offsetting insider trades in company common stock. On June 10 and June 15, Kalia executed open-market sales totaling 1,200 shares at prices around $130–$131 per share and an open-market purchase of 600 shares at about $130.76 per share.
After these transactions, Kalia directly holds 40,814 shares of Guardant Health common stock. A footnote states that, based on these trades, the company identified recoverable Section 16(b) short-swing profits of $192, which Kalia has paid back to the company.
Guardant Health, Inc. co-CEO AmirAli Talasaz reported a combination of stock option exercises and share sales tied to the Talasaz and Eskandari 2017 Family Trust. On June 26 and June 29, 2026, the trust sold an aggregate 260,000 shares of common stock in open-market transactions at weighted-average prices around $150–$153 per share, executed across multiple price ranges.
On the same dates, stock options to acquire a total of 254,832 shares of common stock were exercised at a $4.18 per-share exercise price, converting derivative awards into common shares. The common stock and options are reported as held directly or indirectly, with a significant portion attributed to the Talasaz and Eskandari 2017 Family Trust.
Guardant Health director Tariq Musa sold 1,951 shares of Common Stock in an open-market transaction. The shares were sold at an average price of $131.16 per share. After this sale, Musa directly holds 11,048 Guardant Health shares, indicating he retains a significant ongoing equity position in the company.
Guardant Health, Inc. director Myrtle S. Potter reported an open-market sale of Common Stock. She sold 1,556 shares on June 22, 2026 at an average price of $131.16 per share. After this transaction, she directly holds 20,971 Guardant Health shares.
Guardant Health director Roberto Mignone reported routine equity compensation activity, exercising restricted stock units (RSUs) into common shares. On May 21, 2026 and June 21, 2026, RSU conversions of 264 shares each delivered a total of 528 common shares at a stated price of $0.00 per share.
After these transactions, Mignone directly held 9,482 shares of Guardant Health common stock and 7,392 RSUs. Footnotes explain that the RSU award was granted on November 8, 2024 and vests over four years, with 25% vesting on October 21, 2025 and the remaining 75% vesting monthly over the following three years.